BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
Adverse event reporting can be found at the bottom of this page.
BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1
BeneFIX® monitoring
During the course of treatment, appropriate determination of factor IX levels is advised to guide the dose to be administered and the frequency of repeated infusions.1
Dose based on bodyweight may require adjustment in underweight or overweight patients. Individual patients may vary in their response to factor IX, demonstrating different half-lives and recoveries.1 |
|
In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor IX activity) is indispensable.1 |
|
When using an in vitro thromboplastin time (aPTT)-based one stage clotting assay for determining factor IX activity in patients' blood samples, plasma factor IX activity results can be significantly affected by both the type of aPTT reagent and the reference standard used in the assay. This is of importance particularly when changing the laboratory and/or reagents used in the assay.1 |
|
Monitoring
Administration and storage
The R2 device is used for reconstitution of BeneFIX® by injection.
Recommended dosing schedules1
No two days are the same. No two patients are the same. BeneFIX® offers frequent, flexible dosing so your patients are covered for everyday life.1–3
BeneFIX® in the real-world setting
rFIX products like BeneFIX® are effective at preventing bleeds in everyday settings.4
** This is an optional area where footnotes can live.
Contact us
Contact a member of the Pfizer haemophilia team.
** This is an optional area where footnotes can live.
- BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
- Shapiro AD et al. Blood 2005;105(2):518–525.
- Berntorp E, Andersson N. Semin Thromb Hemost. 2016;42:518–525.
- Chhabra A et al. Blood Coagul Fibrinolysis 2020;31(3):186–192.
Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No
OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?